CCSD code M0813 – Percutaneous biopsy of renal transplant

Key takeaways

CCSD Code M0813 covers percutaneous needle biopsy of a renal transplant (allograft), not a native kidney.

Open biopsy of a native kidney is M0814, so confirm transplant status in the record before coding.

Ultrasound guidance is not automatically bundled, so check the insurer’s current bundling rules before reporting it separately.

Most UK private insurers require pre-authorisation before the procedure, and retrospective approval is rarely granted.

Histopathology on the biopsy cores is billed separately by the pathology laboratory, under the same episode date.

CCSD Code M0813: Definition and clinical scope

CCSD Code M0813 is listed in the CCSD (Clinical Coding and Schedule Development Group) schedule with the official descriptor “Percutaneous biopsy of renal transplant.” It sits in Chapter 12, Urinary system and male reproductive organs, and describes a needle biopsy of a transplanted kidney rather than a native one. Whether the kidney is a graft or the patient’s own decides which code applies.

The schedule is maintained by the CCSD Group, made up of major private healthcare insurers. UK private insurers use it to pay for specialist procedures. M0813 covers obtaining the tissue. The pathology analysis of the cores is billed separately under the appropriate histopathology code. Neighbouring Chapter 12 codes are indexed in the CCSD code library.

The procedure: What a percutaneous renal transplant biopsy involves

A percutaneous renal transplant biopsy takes one or more tissue cores from a transplanted kidney with a spring-loaded needle. The device is typically a 16G or 18G tru-cut needle. The anatomy differs from a native kidney biopsy. A transplant kidney sits in the iliac fossa rather than the retroperitoneum. It is reached from the front and is usually easier to see on ultrasound.

The British Transplantation Society (BTS) sets the standard of care for this procedure. Pre-procedure workup includes a coagulation screen, platelet count, and blood pressure control. The procedure itself typically follows these steps:

1. Pre-procedure assessment: Coagulation screen (INR, APTT, platelet count), blood pressure optimised to below 160/90 mmHg, and consent obtained in writing.
2. Patient positioning: Supine position, with the transplant kidney location confirmed clinically and by ultrasound scan.
3. Ultrasound targeting: Real-time ultrasound guidance is used to identify the biopsy zone (lower pole cortex preferred), avoiding large vessels and the collecting system.
4. Needle passes: Typically one core is obtained per pass. At least two adequate cores containing cortical tissue are needed for Banff assessment.
5. Post-procedure monitoring: Observation for four to six hours (most units require six), watching for haematuria, haematoma, and haemodynamic instability. A post-biopsy ultrasound may be performed to exclude perinephric haematoma.

The percutaneous approach is distinct from open surgical biopsy (performed under general anaesthesia via a formal incision) and from laparoscopic biopsy. CCSD Code M0813 covers only the percutaneous approach; open or laparoscopic access would fall under different codes.

Clinical indications for CCSD Code M0813

The clinical indication documented in the patient record is the primary driver of medical necessity for any M0813 claim. UK private insurers will not authorise the procedure without a clearly stated clinical justification linking the biopsy to one of the following recognised indications.

Histological reporting: Banff classification and what coders need to know

The Banff classification is the standard histological grading framework for renal allograft biopsies. It is published by the Banff Working Group and referenced in BTS guidelines and international nephrology protocols. When a biopsy obtained under M0813 reaches the histopathology laboratory, the pathologist reports findings using Banff diagnostic categories.

Billing staff need the Banff terms because the pathology report uses them, and they reappear in the supporting documents sent to insurers. The categories below use the legacy Banff 1997/2007 category numbers; current reports use the Banff 2019 lesion-score classification.

• Banff 1 (Normal): No rejection features. May still support M0813 if clinical indication was documented.
• Banff 2 (Antibody-mediated changes): Includes active and chronic antibody-mediated rejection. Donor-specific antibody titre should accompany the claim.
• Banff 3 (Borderline): Suspicious for acute T-cell-mediated rejection but below threshold. Clinical correlation required.
• Banff 4 (T-cell-mediated rejection): Classified by grade (I, II, III). Insurers generally accept this as clear medical necessity.
• Banff 5 (Interstitial fibrosis and tubular atrophy / IFTA): May reflect chronic injury from rejection or CNI toxicity. Documenting the clinical trajectory strengthens the claim.
• Banff 6 (Other): Includes recurrent disease, de novo glomerulonephritis, BK virus nephropathy.

The histopathology report is billed separately. CCSD Code M0813 covers obtaining the tissue, and the laboratory analysis is coded under the relevant CCSD pathology chapter.

Documentation requirements for M0813 renal transplant biopsy claims

Missing documentation is a leading reason UK private insurers query or deny M0813 claims. Every element below should be in the clinical record before a claim is submitted.

• Documented indication: The reason for the biopsy (rising creatinine, proteinuria, suspected rejection, surveillance protocol), stated in the referral letter or outpatient clinic note.
• Pre-procedure blood results: INR, APTT, platelet count, and current serum creatinine. BTS guidance treats these as standard pre-biopsy checks to reduce bleeding risk.
• Blood pressure record: Documented control below the unit’s pre-biopsy threshold in the procedure note.
• Written consent: Signed consent form covering the procedure, anaesthetic risks (if sedation used), and possibility of haematoma or arteriovenous fistula.
• Imaging guidance record: A statement in the procedure note confirming that ultrasound guidance was used (or was not used, where freehand technique was employed).
• Number of cores obtained: The operative/procedure note must state how many tissue cores were taken and their adequacy.
• Post-procedure observation: Duration of post-biopsy monitoring, haemodynamic observations, urinalysis result, and any complications documented.
• Pre-authorisation reference number: Where pre-auth was obtained, the authorisation reference must appear on the invoice and the supporting documentation.

Capturing the procedure note and consent on structured digital forms reduces the risk of a missing field at claim submission. A template with required fields for bloods, consent and core count stops an incomplete note from being saved.

Imaging guidance: Is it included in CCSD Code M0813 or billed separately?

Imaging guidance is not part of the M0813 descriptor, which reads only “percutaneous biopsy of renal transplant.” Under standard CCSD bundling convention, guidance is separately codeable when the descriptor does not include it. Insurer fee schedules and bundling rules vary, though, and this is a frequent unbundling error in nephrology billing.

Before reporting a separate ultrasound guidance code alongside M0813, verify the following with the specific insurer:

• Check the insurer’s current fee schedule and bundling guidance. The Healix fee schedule and its unbundling guidelines, for example, set out rules on imaging add-on codes.
• Confirm which radiology or ultrasound code the insurer accepts alongside M0813, since insurers reference different radiology codes for real-time guidance.
• Ensure the pre-authorisation reference covers both the biopsy and any imaging guidance code if they are submitted together on the same claim.

Never report an imaging guidance code simply because ultrasound was used. Bundling rules exist to prevent double-claiming for imaging that is integral to performing the biopsy safely. Whether guidance is included depends on the current CCSD schedule version and the insurer’s policy, and the two can differ.

Neighbouring CCSD codes: Transplant vs native kidney biopsy

The key distinction in kidney biopsy coding is transplant versus native kidney. Coding a native kidney biopsy for a renal allograft, or the reverse, is a common reason claims are queried in transplant units.

Open biopsy of a native kidney is M0814. For M0813, the clinical record must confirm the patient has a functioning renal transplant. A transplant letter, the original transplant operation note, or a nephrology clinic letter confirming allograft function all serve as evidence. Where any doubt exists about code boundaries, refer to the current CCSD technical guide (October 2025) for the definitive descriptor wording.

Pre-authorisation requirements from UK private insurers

Most UK private insurers require pre-authorisation before a renal transplant biopsy under M0813. Retrospective authorisation is rarely granted, and a refusal means the claim is written off. The table below outlines typical requirements across the main payers. Requirements change, so confirm current policy with each insurer before the procedure date.

For Bupa specifically, the Bupa CCSD coding guide on pabau.com covers how Bupa applies CCSD codes and the general pre-authorisation process for interventional procedures. Check Bupa’s live portal for M0813 approval requirements, as its clinical policies change.

Common reasons M0813 claims are denied

M0813 denials cluster around a predictable set of documentation and coding errors. Catching them before submission costs less than appealing afterwards.

Each of these denials maps to a step in the claim path, and the first two steps have to happen before the procedure date.

Surveillance vs clinically indicated biopsies: Does the coding differ?

Protocol surveillance biopsies and clinically indicated biopsies both use CCSD Code M0813. They differ in documentation requirements and in how insurers cover them. The code itself does not change; what changes is the justification needed to support the claim.

A clinically indicated biopsy is triggered by an acute or subacute change, such as rising creatinine, new proteinuria or suspected rejection. Medical necessity is usually straightforward to document because the clinical trigger is objective and time-stamped.

A surveillance (protocol) biopsy is scheduled at fixed post-transplant intervals regardless of symptoms, typically at three months and twelve months post-transplant under BTS protocols. These biopsies aim to detect subclinical rejection before it becomes clinically apparent. Some UK private insurers exclude or restrict cover for protocol biopsies, classing them as preventive rather than therapeutic. Where cover is uncertain, the billing team should:

• Obtain written pre-authorisation explicitly stating that the procedure is a scheduled protocol biopsy (not a clinically triggered one).
• Reference the BTS transplant monitoring guideline as the basis for the surveillance schedule in the supporting documentation.
• Check whether the insurer’s current policy for M0813 distinguishes between surveillance and indicated biopsies, as some insurers require an additional clinical rationale for protocol-driven claims.

Additional codes commonly billed alongside M0813

A renal transplant biopsy episode often involves services beyond the core M0813 procedure. Billing them correctly, without over-claiming or mis-bundling, depends on knowing which services sit outside the biopsy itself.

How to record and bill M0813 in practice management software

Many M0813 coding errors happen at charge entry, when a biller codes from memory instead of the patient record. Pabau’s claims management supports insurance billing in the UK. It sends claims through Healthcode to insurers such as Bupa, AXA Health, WPA, Vitality and Aviva.

Each pre-authorisation is stored as a case. Attach the case when booking, and the authorisation code follows the appointment through to the claim. The private practice billing software then tracks each claim from submission to payment, so a queried M0813 claim surfaces early. The key steps in the billing workflow are:

1. Confirm transplant status from the patient record before selecting M0813 rather than a native kidney code.
2. Attach the pre-authorisation case to the booking, so the authorisation code carries through to the invoice.
3. Add any separately approved add-on codes (ultrasound guidance, anaesthetic) to the same episode.
4. Attach the procedure note and supporting blood results to the invoice before submission.
5. Submit to the insurer via Healthcode or the insurer’s direct portal, and record the submission date for follow-up.

Bill CCSD procedures without the paperwork headache

Pabau sends UK insurance claims through Healthcode and carries each pre-authorisation code from booking to claim. See how it works for your practice.

Book a demo

Conclusion

Code M0813 only when the record proves the kidney is a graft, and have the authorisation reference in hand before the biopsy is booked. Those two checks decide most M0813 claims before a pathologist sees a core.

Treat imaging guidance as an open question on every claim. Each insurer’s current bundling rules settle it, so check them payer by payer rather than carrying one answer across your list.

Pabau keeps the pre-authorisation code attached from booking to claim and submits through Healthcode, which guards against two common M0813 denial triggers. Book a demo to see the claim workflow for UK private nephrology billing.

Continue your research

Need to understand how Bupa processes CCSD codes? Bupa CCSD codes guide covers Bupa’s procedure code structure and how to submit claims correctly.

Billing an open biopsy of a native kidney instead? CCSD Code M0814 explains the open native kidney biopsy code and how it differs from percutaneous approaches.

Coding open kidney surgery with no specific code? CCSD Code M0800 covers other open operations on the kidney or renal pelvis.

Draining a perinephric abscess? CCSD Code M0880 sets out the open drainage code and the ICD-10 code claims usually pair with it.

Frequently asked questions